Condition: Cutaneous Squamous Cell Carcinoma · Sponsor: Melanoma Institute Australia
The goal of this study is to test neoadjuvant therapy with the dual inhibition of Programmed cell death protein 1 (PD-1) and lymphocyte activation gene 3 (LAG-3) immune checkpoint pathways in a cohort of treatment-naïve, resectable stage II to IV cutaneous squamous cell carcinoma on the pathological response rate (pCR) and recurrence-free survival.
This description comes directly from the study's public registry record.
Monica Osorio · +61 2 9911 7296 · monica.osorio@melanoma.org.au
Maria Gonzalez · +61 2 9911 7200 · maria.gonzalez@melanoma.org.au
Always discuss trial participation with your own doctor first.
| Melanoma Institute Australia | Wollstonecraft, New South Wales, Australia | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06288191